Offering 2,20,22,100 equity shares at ₹92 per share on a 1:1 rights basis
The consolidated financial results for the quarter ending Dec 31, 2024 (Q3)
Veeda Clinical Research Files DRHP For Around 1,000 Cr IPO
The consolidated financial results for the quarter ending Dec 31, 2024 (Q3)
The consolidated financial results for the quarter ending Dec 31, 2024 (Q3)
NSE Q2FY24 Results Announced
Intimation for Investor/Analyst Call scheduled on Monday, February 12, 2024
FY24 Results Declaration
Xtranet Valuation Report